Mixed results reported for nivolumab/ipilimumab in cisplatin-ineligible mUC
EV plus pembrolizumab doubles CR rate vs chemotherapy in la/mUC
Adjuvant pembrolizumab continues to show DFS, OS benefits for ccRCC at 5-year assessment
EFS benefit is seen with sasanlimab in CIS and T1 NMIBC